InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（1 笔）
内部人交易记录
高级管理人员已披露买入
0
已披露卖出
1
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the full record of transactions filed by Kraus Carl N, Chief Medical Officer. Director active across 1 company, notably Aquestive Therapeutics, Inc.. In total, 6 filings have been logged. Split: 0 buy · 1 sell. Total volume traded: €122k. Activity tracked since 9 August 2023. The latest transaction was filed on 15 October 2025 (Cession). Regulator: SEC (Form 4). The full history is free.
Companies and markets linked to Kraus Carl N
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报6 总计
20,272 股@ US$7.000.015% mcap50.0% 占其流量Common StockSEC:0001214659-25-015047:0
10,819 股@ US$3.9011.5% 占其流量Common StockSEC:0001214659-25-011823:0
70,000 股0Common StockSEC:0001214659-25-004225:0
10,819 股@ US$3.4310.8% 占其流量Common StockSEC:0001214659-24-014226:0
112,500 股0Common StockSEC:0001214659-24-004306:0
150,000 股0Common StockSEC:0001214659-23-010919:0
6 条申报中的 6 条
About Kraus Carl N
Kraus Carl N is the Chief Medical Officer of Aquestive Therapeutics, Inc. He is responsible for the medical strategy and clinical development of the company, which focuses on innovative treatments. His role is essential in ensuring that Aquestive's products meet safety and efficacy standards.
